Clinical Trial Update: PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

PLX2853 was evaluated as a single agent and in combination with carboplatin in platinum-resistant epithelial ovarian cancer and other gynecologic neoplasms. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Gynecologic Neoplasms

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PLX2853

Snippet

Sponsor: Opna Bio LLC | Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-04